Cargando…
Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy
SIMPLE SUMMARY: Since neuroaxonal damage and loss are observed in chemotherapy-induced peripheral neuropathy (CIPN) and results in permanent disability, detecting and monitoring neuropathy with a serum biomarker would be advantageous in identifying the development, severity, and resolution of CIPN....
Autores principales: | Cavaletti, Guido, Pizzamiglio, Chiara, Man, Albert, Engber, Thomas M., Comi, Cristoforo, Wilbraham, Darren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486738/ https://www.ncbi.nlm.nih.gov/pubmed/37686492 http://dx.doi.org/10.3390/cancers15174216 |
Ejemplares similares
-
Plasma neurofilament light chain concentration in the inherited peripheral neuropathies
por: Sandelius, Åsa, et al.
Publicado: (2018) -
Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy
por: Kim, Su-Hyun, et al.
Publicado: (2020) -
Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin
por: Burgess, B. L., et al.
Publicado: (2022) -
Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy
por: Fumagalli, Giulia, et al.
Publicado: (2021) -
Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy
por: Cavaletti, Guido, et al.
Publicado: (2020)